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ABSTRACT 
Mushrooms represent a major yet largely untapped source of therapeutically useful bioactive compounds. Despite mushrooms were in use since 
antiquity in traditional folk medicine attempts to isolate their bioactive components and to elucidate their medicinal properties have started only 
recently. Many pharmaceutical substances with unique properties were recently extracted from mushrooms and made their way all over the world. 
A number of medicinal mushrooms have been identified to possess anticancer effects recently. Some of the well-known examples are Lentinan from 
Lentinus edodes, Krestin from Trametes versicolor, Ganopoly from Ganoderma lucidum and Schizophyllan from Schizophyllum commune. We 
investigated the anticancer activities of a number of medicinal mushrooms in our laboratory. Some of the recent scientific evdences on the 
anticancer activities of Ganoderma lucidum, Phellinus rimosus, and Fomitopsis pinicola are discussed in this short review. 
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INTRODUCTION 
According to World Health Organization (WHO) cancer is the second 
major cause of morbidity and mortality claiming over 9.6 million 
lives worldwide every year. Although significant contributions have 
been made on our understanding on the biology of cancer, discovery 
of anticancer drugs has been an extraordinary challenge. Thus, 
anticancer drug development remains one of the target areas of 
biomedical research. Despite the phenomenal progress in synthetic 
drugs, natural products still remain a major source for large number 
drugs. Hence, attention has now been focused on natural products 
for anticancer drug discovery. Despite the tremendous progress in 
modern medicine with the phenomenal developments in synthetic 
medicine, plants and their derivatives continue to be important 
sources of drugs throughout the world. Many clinically important 
drugs such as aspirin, digitoxin, progesterone, cortisones, morphine, 
vincristine, vinblastine, placitaxel (taxol) and several others have 
been derived directly or indirectly from higher plants. 
Natural product-based medicines have originated from various 
sources, including plants, fungi and animals. Bioactive substances 
from these sources possess enormous structural and chemical 
diversity. Fungi have contributed enormously to modern medicine. 
A number of life-saving drugs such as penicillin, cyclosporine, ergot 
alkaloids and many others were developed from fungi. However, 
these drugs were all isolated and developed from micro-fungi. 
Mushrooms are macrofungi. The number of mushroom species on 
the earth is estimated to be 140,000 and currently, 14,000 to 15,000 
species are known of which over 1800 species are considered to 
have medicinal properties [1]. A large number of bioactive chemical 
compounds have been isolated from the fruiting bodies, mycelia and 
spores of mushrooms. 
The use of mushrooms as food and their use in medicine has been 
mentioned in ancient medical treatise, Charak Samhitha as early as 
3000 B C. Most of the traditional knowledge about mushrooms 
comes from Far East, China, Japan, Korea and the east of Russia [2]. 
However, mushrooms represent a major yet largely untapped 
source of pharmaceutical products. Many pharmaceutical 
substances with unique properties were recently extracted from 
mushrooms and made their way all over the world. Some of the most 
recently isolated and identified compounds from medicinal 
mushrooms have shown promising immunomodulatory, antitumor, 
cardioprotective, antiviral, antibacterial, antiparasitic, 
hepatoprotective, and antidiabetic properties. Modern scientific 
studies on medicinal mushrooms have expanded exponentially 
during the last two decades not only in Japan, Korea, and China but 
also in USA [3]. 
One of the most important medicinal properties of mushrooms that 
have attracted the attention of public in recent years is their 
anticancer properties. Ikekawa and his coworkers published one of 
the first scientific reports on the antitumor activity of fruiting bodies 
of mushrooms in 1969. Thereafter three major anticancer drugs 
were developed from medicinal mushrooms, Krestin from Coriolus 
versicolor, Lentinan from Lentinus edodes, Schizophyllan from 
Schizophyllum commune. All the three were β-glucan 
polysaccharides. Krestin was developed in Japan from the strain of 
Trametes (Coriolus) versicolor, whereas Polysaccharide-peptide 
(PSP) in China was developed from the cultured mycelium of 
another strain of this mushroom. Lentinan, Krestin (PSP) and 
Schizophyllan are approved in Japan as prescription drugs for the 
treatment of cancer [4]. 
Over the past two or three decades, scientific and medical studies in 
Japan, China, Korea and, more recently in United States have 
increasingly demonstrated the potent and unique properties of 
mushroom extracted compounds for the prevention and treatment 
of cancer. The ability of mushrooms to inhibit tumor growth and 
modulate immune functions was demonstrated by several 
experimental studies and soon it became obvious that the tumor-
inhibiting activity was contained in the polysaccharide fractions.  
Several mushroom polysaccharides have proceeded through Phase 
1, II and III clinical trials and are extensively and successfully used in 
Asian countries to treat various types of cancers [5]. Medicinal 
mushroom products, especially, polysaccharides were developed 
with clinical and commercial purpose, Krestin (PSK) and PSP 
(Polysaccharide-protein complex) from Trametes versicolor; 
Lentinan from Lentinus edodes, Schizophyllan (Sonifilan, Sizofiran or 
SPG) from Schizophyllum commune, D-fraction from Grifola frondosa, 
Befungin from Inonotus obliququus; Ganopoly from Ganoderma 
lucidum and many others [5]. 
Experimental studies carried out at Amala Cancer Research Centre 
have found that number of medicinal mushrooms occurring in India 
was found to possess antitumor activity in animal models. However, 
further experimental studies revealed significant anticancer activity 
of Ganoderma lucidum, Phellinus rimosus, Morchella species, 
Pleurotus species, Volvariella volvaceae and Fomitopsis pinicola. 
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Ganoderma lucidum (Fr.) P. Karst 
G. lucidum (Fr.) P. Karst (fig. 1), popularly known as Reishi or Ling 
Zhi has the longest historical use as medicine dating back to 4000 y. 
This mushroom is used in traditional Chinese and Japanese 
medicines. Reishi is known as ‘Plant of immortality’ and key 
ingredient in the ‘Elixir of life’. Although there were several fungi in 
folklore medicine, G. lucidum was considered as sacred. In Chinese 
folklore, LinghZhi is considered a panacea for all types of diseases. A 
large number of medicinal properties have been reported for this 
mushroom. Species of Ganoderma have been reported to occur 
throughout the world. G. lucidum is found to occur widely in India, 
particularly in tropical area. Investigations carried out at Amala 
Cancer Research Centre showed that G. lucidum occurring tropical 
south India possessed significant antioxidant, anti-inflammatory, 
antinociceptive, antimutagenic, anticarcinogenic, antitumor, 
hepatoprotective, nephroprotective and cardioprotective propeties. 
 
 
Fig. 1: Ganoderma lucidum 
 
Bioactive components 
A large number of bioactive chemical compounds were extracted 
from the fruiting body, mycelia and spores of Reishi-G. lucidum. Over 
300 reports have been published on the chemical constituents of G. 
lucidum and related species. Approximately 400 bioactive 
compounds have been reported from the fruiting body, mycelium, 
and spores of G. lucidum. The bioactive molecules include 
polysaccharides, triterpenes, ganoderic acids, phenols, amino acids, 
lignin, vitamins, nucleosides, nucleotides, sterols, steroids, proteins, 
and unsaturated fatty acids, inorganic ions such as Mg, Ca, Zn, Mn, 
Fe, Cu and Ge [6]. However, polysaccharides and triterpenes are the 
two major groups of bioactive compounds present in G. lucidum [7]. 
Polysaccharides of Reishi are the most important component and 
represent structurally–diverse biological macromolecules with wide 
range of biological and physiochemical properties [8]. More than 
200 polysaccharides, including protein-bound polysaccharides have 
been reported from G. lucidum. The major bioactive polysaccharides 
isolated from Ganoderma species are β 1-3 and β 1-6 D glucans (fig. 
2) with molecular weight ranging from 4x105 to 1x 106. 
The second most important biologically active compound in Reishi is 
triterpenoids/triterpenes. This group has received considerable 
attention because of their well-known pharmacological activities. 
More than 130 oxygenated triterpenes (mostly lanostane-types) 
have been isolated till recently from the fruiting bodies, spores, 
mycelia, and culture media of Reishi-G. lucidum [9]. These 
triterpenes could be divided into C30, C27, and C24 compounds 
according to the number of carbon atoms and based on the structure 
and functional groups (fig. 3)). In general, they are low molecular 
weight compounds. These compounds isolated from Reishi were 
intensively studied during 1980s. Currently, nearly, 136 triterpenes 
with varying structures have been isolated [5]. 
Anticancer activity  
Ganoderma species and their extracts are known as a traditional 
remedy in Chinese medicine for the prevention and treatment of 
cancer [10]. Numerous pharmacological investigations 
demonstrated that hot water extract of G. lucidum inhibited tumor 
growth in tumor-bearing mice. Several studies carried in our 
laboratory and elsewhere have demonstrated the significant 
antitumor effect of G. lucidum [11, 12]. The alcoholic extract has 
been demonstrated to possess a significant effect on mammary 
adinocarcinoma and skin papilloma [13]. 
The most important constituents of G. lucidum are terpenoids and 
polysaccharides. Both of these constituents show remarkable 
antitumor activity [14]. Triterpenes isolated from G. lucidum were 
found to have cytotoxic activity against several tumor cell lines. The 
alcohol extract of G. lucidum was shown that it inhibited cell 
proliferation in a dose and time-dependent manner. Triterpene 
fraction of G. lucidum significantly inhibited human hepatoma cells. 
Oxygenated triterpenes isolated from G. lucidum spores also showed 
direct cytotoxicity in vitro on tumor cell lines [15]. G. lucidum 
triterpenes were shown to possess profound activity against 
leukemia, lymphoma, and multiple myeloma. 
The antitumor effect of G. lucidum was mediated by cytokines 
released from activated T lymphocytes and macrophages. The 
currently available information suggests that intrinsic 
immunological mechanisms are involved in the antitumor activity of 
G. lucidum. Antitumor effect also has been demonstrated by 
inhibiting angiogenesis. The angiogenesis potential might direct 
inhibition of vascular endothelial proliferation or decrease growth 
factor expression of tumor cells [16]. Clinical studies also showed 
that G. lucidum preparations exerted a synergistic therapeutic effect 
when used in conjunction with radiation and chemotherapy and also 
reduced the side effects of these treatments.  
It is generally accepted that the antitumor and anticancer effects of 
Ganoderma polysaccharides arise from the enhancement of the 
body’s immune system rather than direct cytotoxic effects. However, 
Reishi–G. lucidum was the most active cytotoxic to cancer cells 
among the large number of Basidomycetes species tested. Several 
studies correlated the tumoricidal effects of Reishi with the 
regulation of cancer cell cycling and signaling [17]. Recent 
preclinical studies undertaken in our laboratory showed that G. 
lucidum possessed a significant protective effect against mammary 
adenocarcinoma and skin tumors [13]. 
We carried out preclinical studies to find out the antitumor effect of 
polysaccharides and triterpenes isolated from the fruiting bodies of 
G. lucidum. We found that the polysaccharides inhibited 88% tumor 
growth at a dose of 25 mg/kg body weight and the triterpenes 
inhibited 85% tumor growth at a dose of 10 mg/kg body weight in 
treated animals. However, polysaccharides and triterpenes isolated 
from the mycelia showed higher antitumor activity than fruiting 
bodies. Total terpenes induced apoptosis in MCF-7 cell lines and also 
inhibited 7,12, dimetylbenz [a] anthracene (DMBA) induced 
mammary adenocarcinoma and skin tumor [18]. 
Clinical observation assessment of 547 medium and late phase 
cancer patients treated with Chinese G. lucidum essence showed that 
the death rate of patients in long-term treatment was significantly 
low. A continuous 2-3 mo active treatment with a daily dose of 4-6 g 
G. lucidum essence was proposed. Two randomized trials using G. 
lucidum polysaccharide (Ganopoly) was reported [17]. A total of 34 
advanced patients of different cancer origin were recruited and 
administered 12 w with Reishi capsules at a dose of 1800 mg per 
day and 80% of patients were found to have a series of 
immunological enhancements. In another study, the same capsules 
were administered to 68 lung cancer patients and over 65% of the 
patients were found to have improvements in quality of life. Based 
on available consolidated scientific evidence and clinical 
observations Red mushroom, G. lucidum is highly beneficial to 
cancer patients [10]. 
In a phase I study, methanol extract of G. lucidum was administered 
to men with mild symptoms of bladder outlet obstruction. Male 
volunteers of age above 50 were enrolled. They observed a 
statistically significant reduction in prostrate symptoms at doses of 
6 to 60 mg daily and recommended phase 2 trails. Two randomized 
clinical trials were reported by Gao and coworkers [17]. A total of 34 
cancer patients were recruited, and 12-week Reishi capsules at a 
dose of 1800 mg were given and 80% of the patients were observed 
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significant relief. In another study of 68 lung cancer patients, 
improvement in qualities of life of 65% patients was observed. 
Current experimental evidence indicates that G. lucidum can inhibit the 
signaling pathway responsible for increased migratory potential of 
cancer cells. This process has clinical importance and inhibiting the 
motility of cancer cells can prevent metastatic spread of cancer into 
distant tissues of human body. Angiogenesis is essential for 
invasiveness and metastasis of tumors and accumulating evidence 
indicates that inhibition of angiogenesis is an effective cancer 
preventive and treatment. Antiangiogenisis properties are believed to 
be one of the many possible cancer preventive mechanisms. Hence 
Reishi can be considered as an adjuvant in cancer treatment [15]. 
Almost all toxicity studies with Ganoderma using animal models 
showed a low or no detectable toxicity. There are no reported data 
on long term adverse effects on G. lucidum and its derivatives. The 
aqueous extract of Reishi administered to mice orally at a dose of 
5g/kg body weight for 30 d produced no changes in body weight, 
organ weight, or hematological parameters. The polysaccharides 
fraction at the same dose produced no lethal or serious effects. No 
toxicity was observe in rats, dogs and rabbits [19]. 
 
 
Fig. 2: Structure of Ganoderma polysaccharides (Real mushroom. com) 
 
Among the various classes of chemical constituents isolated from G. 
lucidum Polysaccharides (β-1→3 and β-1→6-D glucans) and 
triterpenoids such as Ganoderic acids are the major compounds 
showing antitumor properties. 
 
 
Fig. 3: Basic structure of main Ganoderma triterpenes, (Benkeblia, N J. Food. Nutri. Diete, 2015) 
 
Phellinus rimosus (Berk) pilat 
Approximately 220 species of Phellinus are known. In traditional 
Chinese medicine hot water extracts of P. linteus have been used to 
treat extensive range of ailments and it is believed to work as a 
‘miracle medicine. Recent studies showed that P. linteus extract 
possessed strong antiproliferative effect [20]. It has been extensively 
studied for the effect on gastric, duodenal, colon, rectal and liver 
cancers. Isolated compounds from cultured mycelia of Phellinus 
species have been used in Korea as medicine, particularly for cancer 
treatment. P. linteus showed antitumor properties owing to its β-(1-
3) linked glycan. 
Polysaccharides isolated from P. gilvus significantly inhibited 
benzo[a]pyrene-induced forestomach carcinogenesis in mice by 
down-regulating p53 expression. P. linteus is a well-known species of 
the genus Phellinus, which attracted great attention due to its potent 
anti-tumor effect and other medicinal properties [21]. The anti-tumor 
activity of the polysaccharides from the fruiting body of this 
mushroom was first reported in 1968, thereafter a wide variety of 
reports have been documented by many investigators. In a 
comparative study of polysaccharides from Basidiomycetes, the 
polysaccharide of P. linteus was the most potent one and produced 
growth inhibition of 96.7% in Sarcoma 180 transplanted 
immunocompetent ICR mice. The active polysaccharide purified from 
mycelia culture of P. linteus also stimulates humoral and cell-mediated 
immunity, and exhibited a wider range of immunostimulation and 
anti-tumor activity than other polysaccharides isolated from 
Basidiomycetes. Phellinus polysaccharide was also suggested to be 
used in immunochemotherapy of cancer because of its effectiveness 
on tumor growth and metastasis through the immunopotentiation 
without toxicity. Many investigators have been demonstrated that the 
mechanism of anti-tumor action of Phellinus mushroom involves 
multiple processes Results of the recent study suggest that the 
biological response modifiers that stimulates proliferation and 
expression of co-stimulatory molecules in B cells, probably by 
regulating protein tyrosine kinase (PTK) and protein kinase C (PKC) 
signaling pathways [22]. Another study showed that the tumoricidal 
activity of peritoneal macrophages against B16 melanoma cells was 
enhanced in a dose-dependent manner. This study concluded that 
Phellius linteus act as an effective immunomodulator and enhances the 
anti-tumoral activity through the up-regulation of nitric oxide (NO) 
and Tumor necrosis factor-α (TNF-α). Extract of P. linteus was 
reported to possess antimutagenic activities and play a role in the 
prevention of cancer by inducing NAD(P)H: quinine oxidoreductase 
and glutathione S-transferase activities and increasing glutathione 
level.  
Direct cytotoxicity of P. linteus against cancer cells inhibits the cellular 
proliferation in human colon cancer cells by induction of apoptosis 
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and G2/M phase arrest. Hispolon (fig. 4), a phenolic compound 
isolated from this mushroom has potential to induce apoptosis of 
breast cancer cells. These findings indicate the potential use of the P. 
linteus extracts in stimulated angiogenesis indicating potential 
therapeutic approach as an adjuvant for chemotherapy [23]. 
 
 
Fig. 4: Hispolon–a bioactive anticancer compound isolated from 
Phellinus species 
 
Phellinus species are mostly tropical mushrooms and 18 species are 
known from Kerala, India. P. rimosus is a parasitic macrofungus that 
grows on jackfruit trees in Kerala (fig. 5). Basidiocarps of this 
mushroom have been used by some tribes in Kerala for curing 
mumps [24]. Intensive investigations were carried out in our 
laboratory on the therapeutic potential of this mushroom. Our 
studies have demonstrated that P. rimosus possessed significant 
antioxidant, anti-inflammatory, antiarthritic, antitumor, 
chemopreventive, hepatoprotective, and radioprotective activities.  
 
 
Fig. 5: Phellinus rimosus 
 
The methanol and ethyl acetate extracts of P. rimosus showed 
significant superoxide anion, hydroxy radical, and nitric oxide 
scavenging and lipid peroxidation inhibiting activities [25]. Ethyl 
acetate and methanol extracts also showed significant cytotoxicity 
against Dalton’s lymphoma ascites (DLA) and Earlich’s ascites 
carcinoma cell lines (EAC). Antitumor activity of the ethyl acetate 
and methanol extracts showed significant antitumor inhibiting 
activity in animal mode [26]. The ethyl acetate extract also showed 
profound anti-mutagenic activity which can be ascribed to its 
mechanism of antitumor activity [27]. Meera and Janardhanan [28] 
reported the isolation of a crude polysaccharide bound protein from 
fruiting bodies of P. rimosus (PPC-Pr). The polysaccharide-protein 
was found significant preventive and curative effects on solid 
tumors in animal models. The aqueous extract of P. rimosus was 
observed significant chemopreventive activity against N-
nitrosodiethylamine (NDEA) induced hepatocellular carcinoma [29].  
The phytochemical analysis revealed that PPC-Pr is a D-glucan-
protein complex with a molecular weight 1,200,000 Da. Anti-tumor 
activity of PPC-Pr was evaluated using the EAC and DLA murine cell 
lines. PPC-Pr administration considerably increased the life span of 
EAC induced ascetic tumor bearing mice. PPC-Pr also showed 
significant preventive and curative effects on solid tumor induced by 
DLA cell line.  
Apoptosis plays an important role as a protective mechanism 
against carcinogenesis by eliminating damaged cells or abnormal 
excess cells proliferation owing to various chemical agents’ 
induction. Emerging evidence has demonstrated that the anti-cancer 
activities of certain chemotherapeutic agents are involved in the 
induction of apoptosis, which is regarded as the preferred way to 
manage cancer. PPC-Pr was able to induce significant cytotoxicity 
against HCT 116 colon cancer cell line. PPC-Pr inhibited the 
proliferation of HCT 116 cells markedly at a dose of 500 and 
1000μg/ml. The characteristic changes of apoptosis were observed 
in the morphology of PPC-Pr treated cells by 4’, 6-Diamidino-2-
phenylindole dihydrochloride hydrate (DAPI) and Acridine orange-
ethidium bromide (AO/EB) staining methods Chromatin 
degradation into multiple internucleosomal fragments is a distinct 
biochemical hallmark for apoptosis and that can be easily detected 
by Comet assay. Comet assay revealed that the apoptotic nuclei were 
more frequent in PPC-Pr treated cells than the control. Thus, by long 
term incubation, PPC-Pr induced cytotoxicity and inhibited the 
tumor cell proliferation in vitro by the induction of apoptosis [30]. 
These studies indicated the potential therapeutic use of P. rimosus as 
a potent anticancer agent. 
Fomitopsis pinicola(Sw) P. Karst 
Fomitopsisis is a genus having more than 40 species of bracket fungi 
in the family fomitopsidaceae. Fomitopsis species have fruit bodies 
that are mostly perennial, with forms ranging from sessile to 
effused-reflexed (partially crust-like and partially pileate). Fruiting 
body texture is typically tough to woody, and the pore surface is 
white to tan or pinkish-colored with mostly small and regular pores. 
Non-toxic Fomitopsis has been traditionally used in folk medicine in 




Fig. 6: Fomitopsis pinicola collected from kashmir conifer forest 
 
F. pinicola is a common mushroom which grows on trees in coniferous 
forests. The mushroom is used for medicinal purposes in Asia and 
reported to provide health, nutrition, and therapeutic benefits. 
Fomitopsis has been reported to contain several chemical constituents 
including ergosterol, phenolics, triterpenes, picolinic acid and many 
other compounds. It has been used in folk medicine as 
antiiinflammatory, antimicrobial, and anticancer agents. Chemical 
compounds reported from F. pinicola include steroids, sesquiterpenes, 
lanostane triterpenoids and triterpene glycosides [31].  
We investigated the antioxidant, anti-inflammatory and anticancer 
properties of F. pinicola collected from Kashmir Himalayas (fig. 6). 
Ethyl acetate and ethanol extracts showed significant antioxidant, 
anti-inflammatory and antitumor activities. The extract also showed 
significant activity against 7, 12 Dimethyl benz [a] anthracene 
(DMBA) induced cancerous papilloma.  
MTT assay showed that ethyl acetate extract was highly effective in 
killing the DLA cells. Even at a low concentration of 50µg/ml, the 
extract caused significant cytotoxicity. Angiogenesis, the process for 
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the production of a large number of capillaries from the blood 
vessels is an important property of malignant cells. Angiogenesis is a 
multi-step process that is important for the establishment of cancer 
growth. Ethyl acetate extract of F. pinicola showed significant 
antiangiogenic property. The extract induced high amount apoptotic 
activity in human colon cancer cell line (HCT 116). These studies 
showed the anticancer effect of F. pinicola bioactives [32]. 
A literature survey reveal that a large number of studies on the 
anticancer activity of F. pinicola have been carried out using cell 
cultures. Wang et al. [33] isolated ergosterol (fig. 7) from the 
chloroform extract of F. pinicola. They observed anticancer 
properties such as pro-apoptotic and inhibition of migration effect of 
this compound. However, further studies are required to 
characterize the anticancer effect of F. pinicola. Such investigations 
would be interesting in order to ascertain the therapeutic benefits of 
this mushroom as an anticancer agent [34]. The added advantage is 
that F. pinicola has been reported nontoxic by anecdotal evidences 
and has been popular in folklore medicine.  
 
 
Fig. 7: Ergosterol-bioactive anticancer compound reported from 
F. pinicola  
 
Future prospects 
Large majority of anticancer drugs available today are generated 
from natural products. However mushrooms remain largely 
unexplored source for drug discovery although they have been 
demonstrated to possess significant antitumor, immunomodulating, 
cytotoxic and antiangiogenic properties. Over the last two decades 
scientific and medical research in Japan, Korea, and recently in 
United States have demonstrated the potent therapeutic properties 
of mushroom bioactives for the prevention and treatment of cancer. 
Some of the most effective antitumor compounds from mushrooms 
included,Krestin from Trametes vesicolor, Lentinan from Lenitnus 
edodes, Schizophyllan from Schizophyllum commune, Grifolan from 
Grifola frondosa, SSG from Sclerotinia sclerotiorum and Ganopoly 
from Ganoderma lucidum. Krestin, Lentinan and Schiziphyllan are 
prescription drugs for treatment of cancer in China and Japan[5]. 
Experimental studies carried out by us at Amala Cancer Research 
Centre found that several mushrooms, namely, G. lucidum, P. 
rimosus, Pleurotus florida, Pleurotus sajor-caju, Morchella esculenta, 
Volvariella volvaceae and F. pinicola possessed profound antitumor 
properties having potential to develop as anticancer agents. 
Anticancer bioactives isolated from medicinal mushrooms include 
polysaccharides, protein bound polysaccharides, steroids, 
sesquiterpenes, lanostane triterpenoids, triterpene glycosides, 
phenolic compounds etc. The current experimental studies 
worldwide reveal the possibilities of several mushroom bioactives 
for the development of anticancer agents or drugs especially as 
adjuvant cancer therapy. They have been suggested to enhance the 
efficacy of treatment and for the alleviation of side effects of chemo 
and radiation therapy [35]. Moreover, numerous clinical trials were 
conducted in recent years to assess the clinical use of a number of 
medicinal mushrooms. The research achievements during the last 
two decades demonstrated that medicinal mushrooms have much to 
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